𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy

✍ Scribed by Kan Yonemori; Koji Tsuta; Chikako Shimizu; Yutaka Hatanaka; Akihiro Hirakawa; Makiko Ono; Tsutomu Kouno; Noriyuki Katsumata; Masashi Ando; Kenji Tamura; Tadashi Hasegawa; Takayuki Kinoshita; Yasuhiro Fujiwara

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
85 KB
Volume
101
Category
Article
ISSN
0022-4790

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Quantitative HER2 protein levels predict
Quantitative HER2 protein levels predict outcome in fluorescence in situ hybridization-positive patients with metastatic breast cancer treated with trastuzumab
✍ Allan Lipton; Wolfgang J. KΓΆstler; Kim Leitzel; Suhail M. Ali; Jeff Sperinde; Jo πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 492 KB πŸ‘ 2 views

## Abstract ## BACKGROUND: Only a portion of breast cancer patients currently selected for trastuzumab therapy respond. ## METHODS: Using a novel assay (HERmark) to quantify total human epidermal growth factor receptor 2 (HER2) expression, the authors examined outcomes in 102 trastuzumab‐treated

c-erbB-2 (HER-2/neu) protein and drug re
c-erbB-2 (HER-2/neu) protein and drug resistance in breast cancer patients treated with induction chemotherapy
✍ Laura M. Vargas-Roig; Francisco E. Gago; Olga Tello; MarΓ­a T. Martin de Civetta; πŸ“‚ Article πŸ“… 1999 πŸ› John Wiley and Sons 🌐 French βš– 71 KB πŸ‘ 2 views

Expression of c-erbB-2 protein has been associated with poor prognosis and poor response to chemotherapy in breast cancer patients. In the present prospective study, we have analyzed whether c-erbB-2, p53 and P170 proteins may be determinants of tumor resistance in locally advanced breast cancer pat